Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:ALTSNASDAQ:SAGENASDAQ:VECT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.50-3.0%$5.75$2.90▼$11.16$283.87M0.583.18 million shs19.92 million shsALTSALT5 Sigma$8.13-6.6%$7.82$1.29▼$10.95$141.91M2.31231,634 shs494,177 shsSAGESage Therapeutics$9.15-1.4%$7.38$4.62▼$13.47$572.98M0.181.29 million shs4.68 million shsVECTVectivBio$16.85$16.85$4.25▼$16.98N/AN/AN/AN/A20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-3.05%-50.34%-36.25%-34.21%-44.04%ALTSALT5 Sigma-6.55%-14.15%-8.45%+96.85%+812,999,900.00%SAGESage Therapeutics-1.40%-1.61%+41.20%+10.51%-15.59%VECTVectivBio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.256 of 5 stars3.51.00.00.02.91.70.6ALTSALT5 Sigma0.4288 of 5 stars0.03.00.00.03.30.00.0SAGESage Therapeutics3.1463 of 5 stars2.02.00.04.02.31.70.6VECTVectivBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$19.00442.86% UpsideALTSALT5 Sigma 0.00N/AN/AN/ASAGESage Therapeutics 2.00Hold$8.93-2.37% DownsideVECTVectivBio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALTS, VECT, SAGE, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/20/2025SAGESage TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.006/17/2025SAGESage TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.506/17/2025SAGESage TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ Hold$8.00 ➝ $9.006/17/2025SAGESage TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$12.006/17/2025SAGESage TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$8.00 ➝ $8.506/16/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K14,194.25N/AN/A$1.74 per share2.01ALTSALT5 Sigma$12.53M11.32N/AN/A$0.49 per share16.59SAGESage Therapeutics$41.24M13.89N/AN/A$7.60 per share1.20VECTVectivBio$27.34MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)ALTSALT5 Sigma-$6.24MN/A0.00∞N/A-38.58%-113.79%-8.96%N/ASAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%7/30/2025 (Estimated)VECTVectivBio-$93.74MN/A0.00∞N/AN/AN/AN/AN/ALatest ALTS, VECT, SAGE, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AALTSALT5 SigmaN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85ALTSALT5 Sigma1.260.830.83SAGESage TherapeuticsN/A9.139.13VECTVectivBioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%ALTSALT5 Sigma6.27%SAGESage Therapeutics99.22%VECTVectivBioN/AInsider OwnershipCompanyInsider OwnershipALTAltimmune4.10%ALTSALT5 Sigma4.90%SAGESage Therapeutics5.50%VECTVectivBio9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableALTSALT5 Sigma17017.45 million16.60 millionN/ASAGESage Therapeutics69062.62 million59.18 millionOptionableVECTVectivBio30N/AN/ANo DataALTS, VECT, SAGE, and ALT HeadlinesRecent News About These CompaniesIronwood’s shares sink as FDA demands new trial for lead drugApril 15, 2025 | msn.comA brain biotech launches with Roche’s spare partsFebruary 13, 2025 | biopharmadive.comBAravax Continues International Expansion with Appointment of Aled Williams as Chief Business OfficerJanuary 21, 2025 | markets.businessinsider.comCDR-Life Appoints Sarah Holland, PhD, as Chief Business OfficerDecember 5, 2024 | finance.yahoo.comRecent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBDNovember 12, 2024 | gut.bmj.comGGraft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsightSeptember 23, 2024 | finance.yahoo.comEtherio Group: 2024 CMI 25September 21, 2024 | meetingsnet.comMCompare with VectivBio Holding AG (VECT)May 29, 2024 | msn.comenGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsMay 15, 2024 | finance.yahoo.comVicore Pharma Holding: Vicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finanznachrichten.deVicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finance.yahoo.comShort Bowel Syndrome Market by 2032: Forecast Report Estimates Significant GrowthApril 5, 2024 | uk.finance.yahoo.comFDA approves DMD treatment from ItalfarmacoMarch 31, 2024 | cen.acs.orgCPipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpointsMarch 18, 2024 | msn.comIronwood Nabs Phase III Win, Still Sees Stock NosediveMarch 1, 2024 | biospace.comBIronwood felled by mixed data in short bowel syndrome trialMarch 1, 2024 | pharmaphorum.comPUPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage studyMarch 1, 2024 | msn.comIronwood's bowel disease treatment meets main goal in late-stage trialFebruary 29, 2024 | reuters.comWhy Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?February 29, 2024 | benzinga.comOnly two sleeps left until February 31!February 29, 2024 | ft.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALTS, VECT, SAGE, and ALT Company DescriptionsAltimmune NASDAQ:ALT$3.50 -0.11 (-3.05%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.47 -0.03 (-0.83%) As of 06/27/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.ALT5 Sigma NASDAQ:ALTS$8.13 -0.57 (-6.55%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$8.25 +0.12 (+1.48%) As of 06/27/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Sage Therapeutics NASDAQ:SAGE$9.15 -0.13 (-1.40%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$9.15 0.00 (0.00%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.VectivBio NASDAQ:VECT$16.85 0.00 (0.00%) As of 06/27/2025VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
